Viking Therapeutics Accelerates Obesity Drug Trial Timeline

Viking Therapeutics has successfully completed patient enrollment for its pivotal VANQUISH-1 Phase 3 clinical trial ahead of schedule, marking a significant development for the biotechnology firm. The company enrolled approximately 4,650 participants to evaluate its obesity treatment candidate VK2735, achieving this milestone well before its original 2026 target.

Market participants responded positively to the news, with Viking’s shares showing strength in pre-market trading Monday. The accelerated recruitment timeline suggests that crucial study data may become available sooner than previously anticipated, potentially compressing the development pathway for the metabolic treatment.

The rapid enrollment of nearly 4,700 participants underscores both strong patient interest and execution capability. The randomized, double-blind VANQUISH-1 study will span 78 weeks Read more...